CII
SGNT

CR Intrinsic Investors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

CR Intrinsic Investors’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-93,677
Closed -$1.91M – 425
2013
Q3 		$1.91M Sell
93,677
-51,473
-35% -$1.15M 0.06% 293
2013
Q2 		$3.04M Buy
+145,150
New +$2.59M 0.11% 232

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CR Intrinsic Investors's SGNT Position: Q4 2013 in Review

CR Intrinsic Investors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2013, closing a stake of 93,677 shares — an estimated $1.91M sold.

CR Intrinsic Investors first reported a position in SGNT in Q2 2013 and held it in 2 quarters. The position peaked at $3.04M in Q2 2013. 99 funds tracked by Wall St. Rank hold SGNT as of Q4 2013.

  • CR Intrinsic Investors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 93,677 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2013, an estimated $1.91M.
  • CR Intrinsic Investors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 2 quarters.
  • CR Intrinsic Investors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $3.04M in Q2 2013.
  • 99 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.